We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

QIAGEN

Qiagen is a provider of sample and assay technologies for molecular diagnostics and applied testing, including comple... read more Featured Products: More products

Download Mobile App




Blood Test Predicts Prostate Cancer Treatment Response

By LabMedica International staff writers
Posted on 17 Jun 2020
Prostate cancer became a bigger killer than breast cancer for the first time, official statistics revealed last year. More...
More than 11,800 men a year - or one every 45 minutes - are now killed by the disease in the UK, compared with about 11,400 women dying of breast cancer.

This means prostate cancer is behind only lung and bowel in terms of how many people it kills in Britain. In the US, the disease kills 26,000 each year. Despite this, it receives less than half the research funding of breast cancer, while treatments for the disease are trailing at least a decade behind.

Oncology specialists led by The Institute of Cancer Research (London, UK) collected blood samples in cell-free DNA Streck tubes (Streck Corporate, La Vista, NE, USA) from 216 patients at three time points; baseline, C3D1 and end of treatment. Cell-free DNA (cfDNA) was extracted from plasma using a Circulating DNA Kit (Qiagen, Hilden, Germany) on a Qiagen QIAsymphony machine. The team extracted 25ng of cfDNA that was used in library preparation, constructed with a custom designed, 58 gene, Qiagen QIAseq Targeted DNA panel, enriched for PI3K/AR pathway genes. Samples were sequenced to mean depth of 3394x on a NextSeq500 machine (Illumina, San Diego, CA, USA).

The scientists analyzed the blood samples from men who were part of a clinical trial of the targeted drug abiraterone with or without an experimental drug, ipatasertib. The results showed that men with high levels of tumor DNA at the start of treatment had a significantly worse outcome. Their disease progressed two and a half months earlier than those negative for 'ctDNA' at the start of treatment. The team looked at blood samples over the course of the treatment with repeated tests, and found those who responded to treatment had the greatest fall in the amount of cancer DNA in their bloodstream. Cancer DNA dropped by 23%, while those who partially responded to treatment had a reduction of 16%. Men whose prostate cancer continued to get worse or stayed the same only saw a reduction of 1% to 4% respectively. The team observed emerging resistance mutations in progression samples, including alterations in TP53, AR, FOXA, PTEN, and PI3K/AKT pathway genes.

Johann de Bono, MD, MSc, PhD, FRCP, FMedSci, a professor of Medical Oncology and a senior author of the study, said, “Our study shows that a simple blood test could help us track how cancer evolves and responds to treatment, initially as part of clinical trials and eventually in routine care. These so-called liquid biopsy tests are minimally invasive, cost-effective and can be performed often and with ease. Tracking prostate cancer with a blood test instead of a painful surgical biopsy could significantly improve patients' quality of life.” The study was presented at the American Society of Clinical Oncology Virtual meeting held May 29 - May 31, 2020.



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.